peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks	peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks	The SVR rates if the patients had IL-28B rs8099917 TT genotype, and GT/GG genotype	991	1255	Compared to patients treated for 24 weeks, the SVR rate in those treated for 48 weeks increased by 10.9% [95% CI: −5.9% to 27.7%] and 65.6% [95% CI: 44.5% to 86.7%] if they had IL-28B rs8099917 TT genotype, and GT/GG genotype, respectively (interaction P = 0.002).
peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks	peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks	The early virologic response (EVR) and the end-of-treatment virologic response	4274	4541	The early virologic response (EVR) (91.5% versus 88.2%, RD: 3.3% [95% CI: −5.3% to 12.0%]; P = 0.45) and the end-of-treatment virologic response (ETVR) (88.3% versus 80.6%, RD: 7.7% [95% CI: −2.7% to 18.0%]; P = 0.15) rates were comparable between the treatment arms.
peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks	peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks	The SVR rates when the patients had BMI >30 kg/m2	5685	5838	The SVR rates of 48-week and 24-week treatment were similar when the patients had BMI >30 kg/m2 (52.6% versus 50.0%, RD: 2.6% [95% CI: −33.5% to 38.8%]).
